Market Currents
ASCO oncology conference: Eli Lilly's (LLY -0.35%) alimta treatment showed promise as a...
-
Monday, June 4, 2012, 11:29 AM ETASCO oncology conference: Eli Lilly's (LLY -0.35%) alimta treatment showed promise as a maintenance drug for treating the most common type of lung cancer in a Phase III study of 939 patients, with the risk of death cut by 22%. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
